- Home
- SNAL vs ALLK Comparison
SNAL vs ALLK Comparison
Compare SNAL & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- ALLK
- Stock Information
- Founded
- SNAL 2000
- ALLK 2012
- Country
- SNAL United States
- ALLK United States
- Employees
- SNAL 97
- ALLK N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- SNAL Technology
- ALLK Health Care
- Exchange
- SNAL Nasdaq
- ALLK Nasdaq
- Market Cap
- SNAL 92.8M
- ALLK 101.0M
- IPO Year
- SNAL 2022
- ALLK 2018
- Fundamental
- Price
- SNAL $2.51
- ALLK $1.11
- Analyst Decision
- SNAL
- ALLK Hold
- Analyst Count
- SNAL 0
- ALLK 4
- Target Price
- SNAL N/A
- ALLK $1.67
- AVG Volume (30 Days)
- SNAL 102.2K
- ALLK 838.5K
- Earning Date
- SNAL 11-13-2024
- ALLK 03-13-2025
- Dividend Yield
- SNAL N/A
- ALLK N/A
- EPS Growth
- SNAL N/A
- ALLK N/A
- EPS
- SNAL 0.08
- ALLK N/A
- Revenue
- SNAL $86,822,973.00
- ALLK N/A
- Revenue This Year
- SNAL $39.43
- ALLK N/A
- Revenue Next Year
- SNAL $26.12
- ALLK N/A
- P/E Ratio
- SNAL $33.21
- ALLK N/A
- Revenue Growth
- SNAL 82.23
- ALLK N/A
- 52 Week Low
- SNAL $0.52
- ALLK $0.54
- 52 Week High
- SNAL $2.65
- ALLK $1.69
- Technical
- Relative Strength Index (RSI)
- SNAL 69.71
- ALLK 53.75
- Support Level
- SNAL $1.75
- ALLK $0.81
- Resistance Level
- SNAL $2.04
- ALLK $1.00
- Average True Range (ATR)
- SNAL 0.24
- ALLK 0.14
- MACD
- SNAL 0.03
- ALLK -0.02
- Stochastic Oscillator
- SNAL 84.45
- ALLK 60.00
About SNAL Snail Inc.
Snail Inc is a global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.